TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00773812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecamylamine
Description: The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One pill is taken once daily.
Study: NCT03391271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photobiomodulation therapy (PBMT)
Description: Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham laser sessions
Description: • The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
Study: NCT01068171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: type of footwear
Description: comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: type of footwear
Description: comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
Study: NCT03450122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT00395226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: zinc sulfate 220 mg bis for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bid for 90 days
Study: NCT02228382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 100 mg and 500 mg tablets, once daily dosage up to 4 years duration
Study: NCT03450122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell-targeting Lentiviral Vector ID-LV305
Description: Given ID
Study: NCT02421835

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive leaf extract
Description: 132 mg of oleuropein per day suspended in olive leaf extract 700 mg
Study: NCT05946148

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin 10mg daily, as add-on to previous treatment regimen.

Intervention type: DRUG
Intervention: Dulaglutide
Description: Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen

Intervention type: DRUG
Intervention: Control Rx
Description: Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
Study: NCT02421835

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive leaf extract
Description: 132 mg of oleuropein per day suspended in olive leaf extract 700 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 700 mg Maltodextrin per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 700 mg Maltodextrin per day
Study: NCT03848832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P presented as an oral solution containing cannabidiol
Study: NCT00510510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 100 µg
Description: Dry powder inhalation once a day for up to 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to NVA237 dry powder inhalation once a day for up to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 200 µg
Description: Dry powder inhalation once a day for up to 28 days
Study: NCT03643666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
Study: NCT03848832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P presented as an oral solution containing cannabidiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral solution
Study: NCT03835806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastikon
Description: This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
Study: NCT03643666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulphate
Description: patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
Study: NCT03835806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocktape
Description: This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
Study: NCT02509442

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diffusion of direct electric stimulation
Description: During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
Study: NCT02932254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
Study: NCT02476526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Volume iso-osmolar non-ionic radio contrast medium
Description: Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Acetylcysteine Inhalation
Description: Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine Inhalation
Description: Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium Bicarbonate Solution
Description: Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Solution
Description: Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 64-MDCT Scanning
Description: Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 64-MDCT Scanning
Description: Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
Study: NCT03346564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ritual training program
Description: Ritual training program including education and demonstration

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Study: NCT02128152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso exoskeleton
Study: NCT03958825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic hepatic sectionectomy
Description: patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open left hepatic sectionectomy
Description: patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
Study: NCT02787278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203 High dose
Description: High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
Study: NCT01068171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: type of footwear
Description: comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collagen dressing with and without silver
Description: silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
Study: NCT01436435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: Atherectomy
Study: NCT02405832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
Study: NCT02787278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203 Low dose
Description: Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study: NCT04289545

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Functional bread
Description: Postprandial effects of bread containing galactomannan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional bread
Description: Postprandial effects of bread containing galactomannan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional bread
Description: Postprandial effects of bread containing galactomannan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional bread
Description: Postprandial effects of bread containing galactomannan
Study: NCT02405832

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge, with sweetener and citrus flavor, administered orally
Study: NCT04289545

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional bread
Description: Postprandial effects of bread containing galactomannan
Study: NCT02613923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GO! To Sleep
Description: Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep information
Description: Participants will receive weekly emails on the health benefits of sleep for 6 weeks
Study: NCT02074501

Intervention type: OTHER
Group type: OTHER
Intervention: training capacity in caregivers
Description: The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge.
Study: NCT03857867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile Stimulation Glove
Description: A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
Study: NCT02613923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: blood sample measured for stress and sleep markers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: blood sample measured for stress and sleep markers
Study: NCT00251732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose (once daily) PPI plus low-dose antidepressant
Description: 20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double dose PPI plus evening placebo
Description: 20 mg. twice daily with a placebo
Study: NCT02613923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insomnia Severity Index (ISI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-12 quality of life survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF-12 quality of life survey
Study: NCT03958032

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
Study: NCT01068171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collagen dressing with and without silver
Description: silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collagen dressing with and without silver
Description: silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
Study: NCT03445871

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood samples will be collected for measuring PG-MTX blood concentration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood samples will be collected for measuring PG-MTX blood concentration.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CRQ
Description: Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CRQ
Description: Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
Study: NCT01157312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate +highly purified uFSH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Study: NCT02350270

Intervention type: OTHER
Intervention: gait and cognitive testing

Intervention type: OTHER
Intervention: gait and cognitive testing

Intervention type: OTHER
Intervention: gait and cognitive testing
Study: NCT04322773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RoActemra iv
Description: single dose treatment with tocilizumab 400 mg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RoActemra sc
Description: single dose treatment with tocilizumab 2 x 162 mg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kevzara sc
Description: single dose treatment with sarilumab 1 x 200 mg subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: management as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: management as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: management as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: management as usual
Study: NCT04029974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ErigoPro
Description: Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
Study: NCT02021045

Intervention type: DEVICE
Intervention: Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)
Description: Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
Study: NCT01485627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training and coaching
Description: Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
Study: NCT00932347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camellia sinensis mouthwash
Description: mouthrinsing, 2 times/day, for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: mouthrinsing, 2 times/day, for 28 days
Study: NCT00354770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: 600mg capsules in varying doses for 12 weeks.
Study: NCT01676675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15.0μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15.0μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30.0μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30.0μg /0.5ml
Description: whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 21 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 21 days interval
Study: NCT00754832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American ginseng extract HT-1001
Description: Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American ginseng extract HT-1001
Description: Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
Study: NCT01487252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At home saliva sampling
Description: Saliva samples taken every half an hour in evening before bedtime.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At home saliva sampling
Description: Saliva samples taken every half an hour in evening before bedtime.
Study: NCT00808795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).